Bone Biologics Corp Net Assets
Bone Biologics Corp net assets. Based on the latest financial reports, Bone Biologics Corp (BBLG) has net assets worth $3.92 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.44 Million) and total liabilities ($512.02K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore BBLG net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.92 Million |
| % of Total Assets | 88.46% |
| Annual Growth Rate | N/A |
| 5-Year Change | -18.22% |
| 10-Year Change | N/A |
| Growth Volatility | 38.76 |
Net Assets of Bone Biologics Corp (2012–2025)
Net assets of Bone Biologics Corp from 2012 to 2025. This chart illustrates how Bone Biologics Corp's net assets have evolved over time, based on quarterly financial data. See Bone Biologics Corp balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Bone Biologics Corp (2012–2025)
The table below shows the annual net assets of Bone Biologics Corp from 2012 to 2025. For live market cap and overall valuation, see Bone Biologics Corp (BBLG) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $5.38 Million | +54.37% |
| 2024-12-31 | $3.48 Million | +19.86% |
| 2023-12-31 | $2.91 Million | -51.13% |
| 2022-12-31 | $5.95 Million | -9.55% |
| 2021-12-31 | $6.58 Million | +148.02% |
| 2020-12-31 | $-13.69 Million | -15.38% |
| 2019-12-31 | $-11.87 Million | -38.02% |
| 2018-12-31 | $-8.60 Million | -2.41% |
| 2017-12-31 | $-8.40 Million | +2.76% |
| 2016-12-31 | $-8.63 Million | -51.98% |
| 2015-12-31 | $-5.68 Million | -53.60% |
| 2014-12-31 | $-3.70 Million | +34.05% |
| 2013-12-31 | $-5.61 Million | -119843.32% |
| 2012-12-31 | $-4.68K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bone Biologics Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8812383800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Bone Biologics Corp Net Assets Breakdown (December 2025)
Bone Biologics Corp net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.79K | 0.03% |
| Other Components | $93.51 Million | 1738.82% |
| Total Equity | $5.38 Million | 100.00% |
Bone Biologics Corp Competitors by Market Cap
The table below lists competitors of Bone Biologics Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Maven Income and Growth VCT 4 PLC
LSE:MAV4
|
$975.37K |
|
Satis Group S.A.
WAR:STS
|
$976.03K |
|
Global Energy Metals Corp
V:GEMC
|
$977.61K |
|
Gentlemens Equity S.A.
PA:MLGEQ
|
$978.53K |
|
EJF Investments Ltd
LSE:EJFI
|
$971.80K |
|
N.W.F Group
LSE:NWF
|
$971.57K |
|
Magnetite Mines Ltd
AU:MGT
|
$970.95K |
|
The Real Good Food Company, Inc.
NYSE:RGFC
|
$966.48K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bone Biologics Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,483,657 to 5,377,548, a change of 1,893,891 (54.4%).
- Net loss of 3,108,991 reduced equity.
- New share issuances of 4,700,341 increased equity.
- Other factors increased equity by 302,541.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.11 Million | -57.81% |
| Share Issuances | $4.70 Million | +87.41% |
| Other Changes | $302.54K | +5.63% |
| Total Change | $- | 54.37% |
Book Value vs Market Value Analysis
This analysis compares Bone Biologics Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.08x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.00 | $0.35 | x |
| 2013-12-31 | $-1.12 | $0.35 | x |
| 2014-12-31 | $-8912.10 | $0.35 | x |
| 2015-12-31 | $-7182.13 | $0.35 | x |
| 2016-12-31 | $-8003.54 | $0.35 | x |
| 2017-12-31 | $-7766.72 | $0.35 | x |
| 2018-12-31 | $-6159.15 | $0.35 | x |
| 2019-12-31 | $-232.07 | $0.35 | x |
| 2020-12-31 | $-267.75 | $0.35 | x |
| 2021-12-31 | $152.47 | $0.35 | x |
| 2022-12-31 | $124.95 | $0.35 | x |
| 2023-12-31 | $11.05 | $0.35 | x |
| 2024-12-31 | $2.30 | $0.35 | x |
| 2025-12-31 | $4.58 | $0.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bone Biologics Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -57.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.08x
- Recent ROE (-57.81%) is below the historical average (-38.09%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-247.40 |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-521.19K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.05 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.31 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-25.04 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.21 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.57 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.24 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-455.46K |
| 2021 | -24.50% | 0.00% | 0.00x | 1.02x | $-2.27 Million |
| 2022 | -24.96% | 0.00% | 0.00x | 1.43x | $-2.08 Million |
| 2023 | -307.91% | 0.00% | 0.00x | 1.29x | $-9.24 Million |
| 2024 | -118.04% | 0.00% | 0.00x | 1.11x | $-4.46 Million |
| 2025 | -57.81% | 0.00% | 0.00x | 1.08x | $-3.65 Million |
Industry Comparison
This section compares Bone Biologics Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bone Biologics Corp (BBLG) | $3.92 Million | 0.00% | 0.13x | $974.27K |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, a… Read more